E-LIB Suche - Ergebnisse für: Viardot, G.

1

Follow-up of the GHSG HD16 trial of PET-guided treatment in..:

Fuchs, M ; Jacob, A.S ; Kaul, H...
http://edoc.mdc-berlin.de/23852/1/23852oa.pdf. , 2024

Link: http://edoc.mdc-berlin.d..

2

CD19-directed CAR T cells as first salvage therapy for larg..:

Dreger, Peter ; Corradini, Paolo ; Gribben, John G...
The Lancet Haematology. 10 (2023) 12 - p. e1006-e1015 , 2023

Link: https://doi.org/10.1016/..

3

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANC..:

Borchmann, P. ; Moccia, A. A. ; Greil, R....
Hematological Oncology. 41 (2023) S2 - p. 881-882 , 2023

Link: https://doi.org/10.1002/..

4

Toxicities at one year follow‐up in patients with advanced ..:

Ferdinandus, J. ; Moccia, A. A. ; Greil, R....
Hematological Oncology. 41 (2023) S2 - p. 363-364 , 2023

Link: https://doi.org/10.1002/..

5

S106: UBTF-ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEF..:

Bastian, L. ; Hartmann, A. ; Beder, T....
HemaSphere. 6 (2022) - p. 7-8 , 2022

Link: https://doi.org/10.1097/..

6

90-yttrium-ibritumomab tiuxetan as first-line treatment for..:

Rieger K ; De Filippi ; R. Lindén...
info:eu-repo/semantics/altIdentifier/wos/WOS:000754337100001. , 2022

Link: http://hdl.handle.net/11..

7

90-yttrium-ibritumomab tiuxetan as first-line treatment for..:

Rieger, K ; De Filippi, R ; Lindén, O...
http://edoc.mdc-berlin.de/21339/1/21339oa.pdf. , 2022

Link: http://edoc.mdc-berlin.d..

8

A phase II trial to evaluate the combination of pixantrone ..:

Hess, G ; Hüttmann, A ; Witzens-Harig, M...
http://edoc.mdc-berlin.de/21536/1/21536oa.pdf. , 2022

Link: http://edoc.mdc-berlin.d..

9

S106: UBTF-ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEF..:

L. Bastian ; A. Hartmann ; T. Beder...
http://journals.lww.com/10.1097/01.HS9.0000843320.74833.6a. , 2022

Link: https://doi.org/10.1097/..

10

Open-label, phase 2 study of blinatumomab after frontline R..:

Katz, D.A ; Morris, J.D ; Chu, M.P...
https://eprints.whiterose.ac.uk/196253/1/Open%20label%20phase%202%20study%20of%20blinatumomab%20after%20frontline%20R%20chemotherapy%20in%20adults%20with%20newly%20diagnosed%20high%20risk%20DLBCL.pdf. , 2022

Link: https://eprints.whiteros..

11

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
boreal:261897. , 2021

Link: http://hdl.handle.net/20..

12

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
boreal:264028. , 2021

Link: http://hdl.handle.net/20..

13

The mTOR inhibitor temsirolimus added to rituximab combined..:

Witzens-Harig, M ; Viardot, A ; Keller, U...
http://edoc.mdc-berlin.de/20956/1/20956oa.pdf. , 2021

Link: http://edoc.mdc-berlin.d..

14

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
https://research.rug.nl/en/publications/a1d0c479-d7ec-41d8-89e8-f1915a808445. , 2021

Link: https://hdl.handle.net/1..

15

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
boreal:264028. , 2021

Link: http://hdl.handle.net/20..